Guided Therapeutics Reports Revenue Growth to $117,462 but Faces Increased Net Loss in Q2 2025

Guided Therapeutics, Inc. reported its financial results for the second quarter of 2025, revealing a revenue of $117,462, a significant increase from $5,720 in the same period last year. This growth is attributed to the shipment of three instrumentation packages and 49,031 RFID chips. However, the company continues to face challenges, posting a net loss of $856,477 for the quarter, compared to a loss of $758,180 in the prior year. The increase in losses is primarily due to higher operating expenses, including a one-time charge of $270,389 related to a compensation package for the CEO.

In terms of operational metrics, Guided Therapeutics has made notable progress in its research and development efforts. The company has reduced its research and development expenses to $132,688 from $221,565 year-over-year, reflecting a strategic focus on cost management. Sales and marketing expenses also decreased by 27% to $50,564, while general and administrative expenses surged by 80.8% to $658,112, largely due to increased payroll and stock-based compensation. The company’s accumulated deficit now stands at approximately $155 million, with a stockholders' deficit of $5.5 million as of June 30, 2025.

Guided Therapeutics is actively pursuing regulatory approvals for its LuViva device, which is designed for non-invasive cervical cancer detection. The company is conducting a clinical trial involving approximately 400 participants, with the goal of obtaining FDA approval. As of August 2025, the company reported that it had surpassed the minimum enrollment target for the study, and data analysis has commenced. Additionally, the company is working towards securing regulatory approval in China, where its partner, SMI, has filed an application with the National Medical Products Administration (NMPA).

The company’s financial position remains precarious, with negative working capital of $5.6 million and a need for ongoing capital to fund operations and regulatory processes. In the first half of 2025, Guided Therapeutics raised $204,500 through a private placement offering and $355,250 from new notes payable. However, the company acknowledges the necessity of further capital raises to sustain operations, and it may need to curtail activities if sufficient funding cannot be secured. The outlook remains uncertain, with the potential for continued operating losses as the company navigates the complexities of the medical device market and regulatory landscape.